This report documents the process and outcome of the assessment and translation of the evidence into guidance recommendations on linkage to care and/or adherence to treatment for HCV, HIV and TB for the ECDC technical report, ‘A systematic literature review of interventions to increase linkage to care and adherence to treatment for hepatitis B and C, HIV and tuberculosis among people who inject drugs’.
For 2020, 29 EU/EEA Member States reported 14 428 cases of hepatitis B virus (HBV) infection. Excluding the five countries that only reported acute cases, the number of cases (14 137) corresponds to a crude rate of 4.2 cases per 100 000 population.
This report presents findings related to the hepatitis B and C continuum of care, policy on testing and treatment, and the impact of the COVID-19 pandemic on hepatitis services in the EU/EEA from the second data collection conducted in 2021.
This report presents the results of the ECDC European Reference Laboratory Network for Pertussis (ERLNPert-Net) external quality assessment (EQA) scheme for Bordetella pertussis PCR, funded by ECDC on behalf of ERLNPert-Net and conducted from April to September 2020. The EQA was organised by the National Institute for Biological Standards and Control (NIBSC), based in Potter’s Bar, United Kingdom (UK).
For 2019, 30 EU/EEA Member States reported 29 996 cases of hepatitis B virus (HBV) infection. Excluding the five countries that only reported acute cases, the number of cases, 29 518, corresponds to a crude rate of 7.4 cases per 100 000 population.
In order to monitor progress towards the United Nations Sustainable Development Goals 2030 target to combat viral hepatitis, this report provides data on hepatitis B and C prevention, incidence, diagnosis, treatment, cure/viral suppression, and mortality in European Union/European Economic Area (EU/EEA) countries with data collected in 2019.